Today: 8 June 2026
Browse Category

NASDAQ:KYMR 8 December 2025 - 4 January 2026

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics shares fell 6.5% to $72.76 on Friday, marking a seventh straight daily loss and leaving the stock down 29% from its early December peak. About 854,000 shares traded as investors shifted focus to 2026 trial milestones and funding. CEO Nello Mainolfi sold 30,000 shares in a pre-arranged plan on Dec. 31. The company raised $602 million in a December stock offering at $86 per share.
4 January 2026
·
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
30 December 2025
··
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Kymera Therapeutics shares jumped 41.6% to close at $94.30 on December 8 after its oral STAT6 degrader KT-621 showed dupilumab-like efficacy and clean safety in a small Phase 1b eczema trial. The company announced a $500 million stock offering the same day, sending shares lower in after-hours trading. Analyst price targets rose, some reaching $138.
9 December 2025
····
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics shares jumped nearly 50% Monday, closing near $96 after hitting an intraday high above $100, following strong Phase 1b results for its oral STAT6 degrader KT‑621 in atopic dermatitis. The trial showed about 98% median STAT6 degradation in blood and 94% in skin lesions. Trading volume was far above normal. Stifel raised its price target as the stock marked a new 52-week high.
8 December 2025
··

Stock Market Today

  • Zepto Files Updated DRHP for $1 Billion IPO Amid Intensified Quick Commerce Competition
    June 8, 2026, 4:34 PM EDT. Zepto, the quick commerce startup, filed an updated draft red herring prospectus (DRHP) with India's Securities and Exchange Board for a $1 billion IPO. The offer consists of Rs 8,010 crore fresh shares and an offer-for-sale from existing investors like Nexus Venture Partners. Valued at $7 billion in October 2025, Zepto plans to expand its dark store network and invest in technology using IPO proceeds. The company reported Rs 7,498 crore revenue in Q4, a 75% rise year-on-year, with a narrowed net loss of Rs 1,539 crore. Zepto aims for a July listing amid fierce competition from Blinkit, Instamart, Amazon, and Flipkart in the fast-growing but highly contested 10-minute delivery segment.

Latest articles

Snap Shares Climb as Debt Markets Send Signal

Snap Drops Again as Wall Street Stays Wary

8 June 2026
Snap plunged 2.1% to $5.64, underperforming a tech rebound, as investors weighed improved cash flow and a recent S&P credit upgrade against ongoing ad-market pressure, cost cuts, and spending on Specs; the stock’s weakness stood out as peers like Pinterest gained, highlighting market doubts about Snap’s ability to sustain growth amid tough competition and uncertain ad budgets.
Dow Drops After Hours, AI Rally Sidesteps Blue Chips

Dow Drops After Hours, AI Rally Sidesteps Blue Chips

8 June 2026
The Dow Jones fell 104.70 points, or 0.21%, to 50,762.08 as tech and chip stocks rebounded sharply, with the Philadelphia SE Semiconductor Index up 6.2% after Friday’s $1 trillion selloff; Apple dropped 1.4% despite its AI event, and investors now await Wednesday’s inflation data and Middle East energy risks as the next key tests for the market’s fragile rebound.
Nasdaq rises as AI names find support after market selloff

Nasdaq rises as AI names find support after market selloff

8 June 2026
Nasdaq surged 1.27% as investors snapped up AI and chip stocks after Friday’s rout, with the Philadelphia Semiconductor Index jumping 6.2%; Citigroup hiked its S&P 500 year-end target to 8,100 on AI demand, but Goldman Sachs warned strong jobs data makes a Fed rate hike more plausible, posing risks to growth stocks if inflation surprises.
Tesla Stock Bounces Over $400 After China Sales Beat—But There’s a Caveat

Tesla Stock Bounces Over $400 After China Sales Beat—But There’s a Caveat

8 June 2026
Tesla shares soared over 5% to $411.66 after a China sales report showed May retail sales up 22.5%, ending a two-month decline, and J.P. Morgan upgraded the stock, citing rising value from autonomy and software; the rally outpaced the Nasdaq as investors bet on Tesla’s China resilience and technology story despite a lofty price-to-earnings ratio of about 378.
Go toTop